JPH0920653A - Dizziness suppressing agent - Google Patents
Dizziness suppressing agentInfo
- Publication number
- JPH0920653A JPH0920653A JP8094342A JP9434296A JPH0920653A JP H0920653 A JPH0920653 A JP H0920653A JP 8094342 A JP8094342 A JP 8094342A JP 9434296 A JP9434296 A JP 9434296A JP H0920653 A JPH0920653 A JP H0920653A
- Authority
- JP
- Japan
- Prior art keywords
- stevia
- dizziness
- hydrochloride
- feeling
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002173 dizziness Diseases 0.000 title abstract 4
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims abstract description 24
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940018415 meclizine hydrochloride Drugs 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 5
- AVZIYZHXZAYGJS-UHFFFAOYSA-N Difenidol hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 AVZIYZHXZAYGJS-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960005058 diphenidol hydrochloride Drugs 0.000 claims abstract description 4
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 claims abstract description 3
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims abstract description 3
- 229940046978 chlorpheniramine maleate Drugs 0.000 claims abstract description 3
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 claims abstract description 3
- 244000228451 Stevia rebaudiana Species 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 241000544066 Stevia Species 0.000 abstract description 21
- 239000003795 chemical substances by application Substances 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract description 9
- 206010013911 Dysgeusia Diseases 0.000 abstract description 5
- 239000000284 extract Substances 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract description 2
- 239000000654 additive Substances 0.000 abstract description 2
- 238000013329 compounding Methods 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- GIPHUOWOTCAJSR-UHFFFAOYSA-N Rebaudioside A. Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC1OC(CO)C(O)C(O)C1OC(C1O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O GIPHUOWOTCAJSR-UHFFFAOYSA-N 0.000 abstract 1
- 238000000855 fermentation Methods 0.000 abstract 1
- 230000004151 fermentation Effects 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 description 12
- 235000019658 bitter taste Nutrition 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 8
- -1 steviorbioside Chemical compound 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000019633 pungent taste Nutrition 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 239000001512 FEMA 4601 Substances 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000019606 astringent taste Nutrition 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940000464 meclizine hydrochloride 50 mg Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 235000019203 rebaudioside A Nutrition 0.000 description 2
- RPYRMTHVSUWHSV-CUZJHZIBSA-N rebaudioside D Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RPYRMTHVSUWHSV-CUZJHZIBSA-N 0.000 description 2
- 229960004499 scopolamine hydrobromide Drugs 0.000 description 2
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- CMCCHHWTTBEZNM-UHFFFAOYSA-N 2-bromo-N-carbamoyl-3-methylbutanamide Chemical compound CC(C)C(Br)C(=O)NC(N)=O CMCCHHWTTBEZNM-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- RLLCWNUIHGPAJY-RYBZXKSASA-N Rebaudioside E Natural products O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@@H](O)[C@@H](O)[C@H](CO)O1)[C@]1(C)[C@@H]2[C@@](C)([C@@H]3[C@@]4(CC(=C)[C@@](O[C@@H]5[C@@H](O[C@@H]6[C@@H](O)[C@H](O)[C@@H](O)[C@H](CO)O6)[C@H](O)[C@@H](O)[C@H](CO)O5)(C4)CC3)CC2)CCC1 RLLCWNUIHGPAJY-RYBZXKSASA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QFVOYBUQQBFCRH-UHFFFAOYSA-N Steviol Natural products C1CC2(C3)CC(=C)C3(O)CCC2C2(C)C1C(C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-UHFFFAOYSA-N 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- WZNRVWBKYDHTKI-UHFFFAOYSA-N cellulose, acetate 1,2,4-benzenetricarboxylate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.OC(=O)C1=CC(C(=O)O)=CC=C1C(=O)OCC1C(OC2C(C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(COC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)O2)OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)O1 WZNRVWBKYDHTKI-UHFFFAOYSA-N 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000003975 dentin desensitizing agent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 229960002819 diprophylline Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- KSCFJBIXMNOVSH-UHFFFAOYSA-N dyphylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)CO)C=N2 KSCFJBIXMNOVSH-UHFFFAOYSA-N 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- RLLCWNUIHGPAJY-SFUUMPFESA-N rebaudioside E Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RLLCWNUIHGPAJY-SFUUMPFESA-N 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- HSFQBFMEWSTNOW-UHFFFAOYSA-N sodium;carbanide Chemical group [CH3-].[Na+] HSFQBFMEWSTNOW-UHFFFAOYSA-N 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- QFVOYBUQQBFCRH-VQSWZGCSSA-N steviol Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)CC1)C[C@H]2[C@@]2(C)[C@H]1[C@](C)(C(O)=O)CCC2 QFVOYBUQQBFCRH-VQSWZGCSSA-N 0.000 description 1
- 229940032084 steviol Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- DRSKVOAJKLUMCL-MMUIXFKXSA-N u2n4xkx7hp Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DRSKVOAJKLUMCL-MMUIXFKXSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、ある特定の鎮暈成分を
含有する経口用医薬品の風味改良に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to the improvement of the flavor of an oral drug containing a specific anti-inflammatory agent.
【0002】[0002]
【従来の技術】ステビアは、Stevia Rebau
diana Bertoniというキク科の多年草の葉
の中に含まれる甘味成分を主体とする甘味料である。一
方、鎮暈剤の有効成分である鎮暈成分、例えば塩酸メク
リジンは苦味を有するなどのため服用感が悪いので、こ
れをを改善することが好ましい。しかしながら、従来の
技術(例えばショ糖を配合する)では苦味のマスキング
は達成するものの他の問題が生じる(上記の例では服用
後に甘味が残ってくどくなる、あるいはカロリーを取り
すぎる)などの不都合があり服用感の改善が十分でなか
った。BACKGROUND OF THE INVENTION Stevia is a Stevia Rebau.
diana Bertoni is a sweetener mainly composed of a sweetening ingredient contained in leaves of a perennial plant of the Asteraceae family. On the other hand, since the antiseptic component, which is the active ingredient of the antiseptic agent, such as meclizine hydrochloride has a bitter taste, it has a bad feeling of ingestion. However, conventional techniques (eg, blending sucrose) achieve masking of bitterness, but have other problems (in the above example, sweetness remains after taking the medicine, or the calories are taken too much). There was not enough improvement in the feeling of taking.
【0003】[0003]
【発明が解決しようとする課題】本発明の目的は、服用
感が改善された鎮暈剤を提供することにある。DISCLOSURE OF THE INVENTION An object of the present invention is to provide a sedative agent with an improved feeling of ingestion.
【0004】[0004]
【課題を解決するための手段】本発明者らは、前記課題
を解決するために、種々の甘味料を用い検討を重ねた結
果、甘味成分としてステビアとある特定の鎮暈成分を組
み合わせると、服用感がよい鎮暈剤が得られることを見
いだし、本発明を完成した。すなわち、本発明は、
(a)塩酸メクリジン、塩酸ジフェニドール、塩酸ジフ
ェンヒドラミンおよびマレイン酸クロルフェニラミンか
らなる群より選ばれる一種または二種以上の薬物(以
下、塩酸メクリジン等と略する)および(b)ステビア
を含有することを特徴とする鎮暈剤である。[Means for Solving the Problems] As a result of repeated studies using various sweeteners in order to solve the above-mentioned problems, the present inventors have found that if stevia and a specific demulcent ingredient are combined as a sweetening ingredient, the dose is increased. It was found that a desensitizing agent with a good feeling was obtained, and the present invention was completed. That is, the present invention
(A) containing one or more drugs selected from the group consisting of meclizine hydrochloride, diphenidol hydrochloride, diphenhydramine hydrochloride and chlorpheniramine maleate (hereinafter abbreviated as meclizine hydrochloride) and (b) stevia. It is a characteristic antiseptic.
【0005】本発明において、ステビアとはステビオサ
イド、レバウディオサイドA、ズルコサイドA、ズルコ
サイドB、レバウディオサイドE、レバウディオサイド
D、ステビオルビオサイド、レバウディオサイドB、ス
テビオル等、公知のステビア抽出物の混合物またはこれ
らのうちの一成分を単離したもののことをいうが、前記
公知のステビア抽出物に、甘味を増すために酵素処理を
行ったものも含む。これらのうちではレバウディオサイ
ドAの含有量が多いものが好ましい。ステビアの有効配
合量は、健康成人で一日5mg〜100mgであり、好ましくは
10mg〜50mgである。ステビアの配合量は塩酸メクリジン
等の種類によって異なるが、塩酸メクリジン等1重量部
に対し、ステビア0.01重量部〜0.1重量部、好ま
しくは0.01重量部〜0.05重量部である。In the present invention, stevia means stevioside, rebaudioside A, zulcoside A, zulcoside B, rebaudioside E, rebaudioside D, steviorbioside, rebaudioside B, steviol, etc. It refers to a mixture of known Stevia extracts or an isolated one of these components, and it also includes the above-mentioned known Stevia extracts that have been treated with an enzyme to increase the sweetness. Among these, those having a high content of rebaudioside A are preferable. The effective amount of Stevia is 5 mg to 100 mg per day in healthy adults, preferably
It is 10 mg to 50 mg. The compounding amount of stevia varies depending on the type of meclizine hydrochloride or the like, but is 0.01 part by weight to 0.1 part by weight, preferably 0.01 part by weight to 0.05 part by weight with respect to 1 part by weight of meclizine hydrochloride or the like. is there.
【0006】本発明のステビア含有の組成物は、そのま
まあるいは必要に応じて他の公知の添加剤、例えば、賦
形剤、崩壊剤、結合剤、滑沢剤、抗酸化剤、コーティン
グ剤、着色剤、矯味矯臭剤、界面活性剤、可塑剤などを
混合して常法により、顆粒剤、散剤、カプセル剤、錠
剤、ドライシロップ剤、液剤(ドリンク剤)などの経口
製剤とすることができる。The stevia-containing composition of the present invention may be used as it is or as required with other known additives such as excipients, disintegrating agents, binders, lubricants, antioxidants, coating agents, and coloring agents. Oral preparations such as granules, powders, capsules, tablets, dry syrups, and liquids (drinks) can be prepared by mixing agents, flavoring agents, surfactants, plasticizers, etc. by a conventional method.
【0007】賦形剤としては、例えばマンニトール、キ
シリトール、ソルビトール、ブドウ糖、白糖、乳糖、結
晶セルロース、結晶セルロース・カルボキシメチルセル
ロースナトリウム、リン酸水素カルシウム、コムギデン
プン、コメデンプン、トウモロコシデンプン、バレイシ
ョデンプン、カルボキシメチルスターチナトリウム、デ
キストリン、α−シクロデキストリン、β−シクロデキ
ストリン、カルボキシビニルポリマー、軽質無水ケイ
酸、酸化チタン、メタケイ酸アルミン酸マグネシウム、
ポリエチレングリコール、中鎖脂肪酸トリグリセリドな
どが挙げられる。Examples of the excipient include mannitol, xylitol, sorbitol, glucose, sucrose, lactose, crystalline cellulose, crystalline cellulose / carboxymethyl cellulose sodium, calcium hydrogen phosphate, wheat starch, rice starch, corn starch, potato starch, carboxy. Sodium methyl starch, dextrin, α-cyclodextrin, β-cyclodextrin, carboxyvinyl polymer, light anhydrous silicic acid, titanium oxide, magnesium aluminometasilicate,
Examples thereof include polyethylene glycol and medium chain fatty acid triglyceride.
【0008】崩壊剤としては、低置換度ヒドロキシプロ
ピルセルロース、カルボキシメチルセルロース、カルボ
キシメチルセルロースカルシウム、カルボキシメチルセ
ルロースナトリウム、クロスカルメロースナトリウム・
A型(アクチゾル)、デンプン、結晶セルロース、ヒド
ロキシプロピルスターチ、部分アルファー化デンプン等
が挙げられる。As the disintegrant, low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose, croscarmellose sodium.
Examples thereof include A type (actisol), starch, crystalline cellulose, hydroxypropyl starch, partially pregelatinized starch and the like.
【0009】結合剤としては、例えばメチルセルロー
ス、ヒドロキシプロピルセルロース、ヒドロキシプロピ
ルメチルセルロース、ポリビニルピロリドン、ゼラチ
ン、アラビアゴム、エチルセルロース、ポリビニルアル
コール、プルラン、アルファー化デンプン、寒天、トラ
ガント、アルギン酸ナトリウム、アルギン酸プロピレン
グリコールエステルなどが挙げられる。Examples of the binder include methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, gelatin, gum arabic, ethylcellulose, polyvinyl alcohol, pullulan, pregelatinized starch, agar, tragacanth, sodium alginate, propylene glycol alginate and the like. Is mentioned.
【0010】滑沢剤としては、例えばステアリン酸、ス
テアリン酸マグネシウム、ステアリン酸カルシウム、セ
タノール、タルク、硬化油、ショ糖脂肪酸エステル、マ
イクロクリスタリンワックス、ミツロウ、サラシミツロ
ウ等が挙げられる。Examples of the lubricant include stearic acid, magnesium stearate, calcium stearate, cetanol, talc, hardened oil, sucrose fatty acid ester, microcrystalline wax, beeswax, and beeswax.
【0011】抗酸化剤としては、例えばジブチルヒドロ
キシトルエン(BHT)、没食子酸プロピル、ブチルヒ
ドロキシアニソール(BHA)、α−トコフェロール、
クエン酸等が挙げられる。As the antioxidant, for example, dibutylhydroxytoluene (BHT), propyl gallate, butylhydroxyanisole (BHA), α-tocopherol,
Citric acid and the like.
【0012】コーティング剤としては、例えばヒドロキ
シプロピルメチルセルロース、ヒドロキシプロピルセル
ロース、メチルセルロース、エチルセルロース、ヒドロ
キシプロピルメチルセルロースフタレート、ヒドロキシ
プロピルメチルセルロースアセテートサクシネート、カ
ルボキシメチルエチルセルロース、酢酸フタル酸セルロ
ース、ポリビニルアセタールジエチルアミノアセテー
ト、アミノアルキルメタアクリレートコポリマー、ヒド
ロキシプロピルメチルセルロースアセテートサクシネー
ト、メタアクリル酸コポリマー、セルロースアセテート
トリメリテート(CAT)、ポリビニルアセテートフタ
レート、セラック等が挙げられる。Examples of the coating agent include hydroxypropylmethylcellulose, hydroxypropylcellulose, methylcellulose, ethylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, carboxymethylethylcellulose, cellulose acetate phthalate, polyvinyl acetal diethylaminoacetate, aminoalkyl meta. Examples thereof include acrylate copolymer, hydroxypropylmethyl cellulose acetate succinate, methacrylic acid copolymer, cellulose acetate trimellitate (CAT), polyvinyl acetate phthalate, shellac and the like.
【0013】着色剤としては、例えばタール色素、酸化
チタン等が挙げられる。界面活性剤としては、例えばポ
リオキシエチレン硬化ヒマシ油、モノステアリン酸ソル
ビタン、モノパルミチン酸ソルビタン、モノラウリン酸
ソルビタン、ポリオキシエチレンポリオキシプロピレン
ブロックコポリマー、ポリソルベート類、ラウリル硫酸
ナトリウム、マクロゴール類、ショ糖脂肪酸エステル等
が挙げられる。Examples of colorants include tar dyes and titanium oxide. Examples of the surfactant include polyoxyethylene hydrogenated castor oil, sorbitan monostearate, sorbitan monopalmitate, sorbitan monolaurate, polyoxyethylene polyoxypropylene block copolymer, polysorbates, sodium lauryl sulfate, macrogol, sucrose. Examples thereof include fatty acid esters.
【0014】可塑剤としては、クエン酸トリエチル、ト
リアセチン、セタノール等が挙げられる。剤形をドリン
ク剤とする場合、必要に応じて他の生理活性成分、ホル
モン、栄養成分、香料等を混合することにより、嗜好性
をもたせることもできる。Examples of the plasticizer include triethyl citrate, triacetin, cetanol and the like. When the dosage form is a drink, it can also be given a palatability by mixing with other physiologically active ingredients, hormones, nutritional ingredients, flavors and the like, if necessary.
【0015】なお、本発明においては、本発明の効果を
損なわない範囲でショ糖などの糖類を配合することもで
きる。また、前記製剤中に塩酸メクリジン等以外の苦味
成分を配合する場合には、苦味成分1重量部に対し、ス
テビア0.02重量部〜0.25重量部、好ましくは
0.02重量部〜0.13重量部を配合する。In the present invention, saccharides such as sucrose may be added within a range that does not impair the effects of the present invention. When a bitterness component other than meclizine hydrochloride or the like is added to the formulation, stevia 0.02 part by weight to 0.25 part by weight, preferably 0.02 part by weight to 0 part by weight, relative to 1 part by weight of the bitterness component. Add 13 parts by weight.
【0016】[0016]
【発明の効果】本発明により、熱および酸に対して比
較的安定で、安全性が高く、安心して使用でき、甘
味の質がマイルドで後味が少なく、非発酵性であり、
熱処理によって褐変作用を起こさない、優れた服用感
を有する鎮暈剤を提供することが可能となった。EFFECTS OF THE INVENTION According to the present invention, it is relatively stable to heat and acid, highly safe, can be used with confidence, has a mild sweetness, a low aftertaste, and is non-fermentable.
It has become possible to provide an antiseptic agent that does not cause a browning effect by heat treatment and has an excellent ingestion feeling.
【0017】[0017]
【実施例】以下に実施例および試験例をあげ、本発明を
具体的に説明する。 実施例1 (処方例) 塩酸メクリジン 50mg ジプロフィリン 50mg 上記薬剤とステビア(10mg)、D−ソルビトール
液、安息香酸、クエン酸ナトリウム、ポリオキシエチレ
ン硬化ヒマシ油および蒸留水を混合し、30ml液剤と
した。EXAMPLES The present invention will be specifically described below with reference to examples and test examples. Example 1 (Formulation example) Meclizine hydrochloride 50 mg Diprophylline 50 mg The above drug and stevia (10 mg), D-sorbitol solution, benzoic acid, sodium citrate, polyoxyethylene hydrogenated castor oil and distilled water were mixed to give a 30 ml solution.
【0018】実施例2 (処方例) 塩酸メクリジン 50mg 臭化水素酸スコポラミン 0.5mg 無水カフェイン 50mg 上記薬剤とステビア(15mg)、バレイショデンプ
ン、ノイシリン、ヒドロキシプロピルセルロース、グリ
チルリチン酸二カリウムを秤量し、均一に混合した後、
分包剤3包を得た。Example 2 (Formulation example) Meclizine hydrochloride 50 mg Scopolamine hydrobromide 0.5 mg Anhydrous caffeine 50 mg The above-mentioned agents and stevia (15 mg), potato starch, noicillin, hydroxypropyl cellulose, and dipotassium glycyrrhizinate were weighed, After mixing evenly,
Three packages were obtained.
【0019】実施例3 (処方例) 塩酸ジフェニドール 25mg 臭化水素酸スコポラミン 0.1mg アミノ安息香酸エチル 70mg ブロムワレリル尿素 200mg 上記薬剤とステビア(10mg)、D−ソルビトール
液、安息香酸、クエン酸ナトリウム、ポリオキシエチレ
ン硬化ヒマシ油および蒸留水を混合し、30ml液剤と
した。Example 3 (Formulation example) Diphenidol hydrochloride 25 mg Scopolamine hydrobromide 0.1 mg Ethyl aminobenzoate 70 mg Bromvalerylurea 200 mg The above-mentioned agents and stevia (10 mg), D-sorbitol solution, benzoic acid, sodium citrate, polypolyamine Oxyethylene hydrogenated castor oil and distilled water were mixed to give a 30 ml liquid formulation.
【0020】試験例1 (実験材料)実験材料には、ステビア含有の検体として
実施例1の液剤(検体A)および実施例1の液剤からス
テビアを除いたもの(検体B)を用いた。 (試験方法)風味に関するアンケート調査について 1)パネラー:20歳代〜50歳代の健常な成人:30
名(内訳として男性:13名、女性:17名)。 2)内容:検体Aと検体Bを飲用してもらい、その後、
アンケート用紙に回答させる方式を用いた。アンケート
の評価方法は、パネラーに各評価項目(匂い/香り
甘味酸味辛味苦味渋み、えぐみこく後味、
さらに、(i)おいしさ(ii)薬らしさ(iii)効き目感
(iv)繰り返しの飲用(v)購入動機(vi)総合評価)
を7段階(非常によい、比較的良い、やや良い、どちら
でもない、やや悪い、比較的悪い、非常に悪い)に分け
て判定してもらった。なお、検体投与は、ダブルブライ
ンドで行い、パネラーには、中味が解らないことになっ
ている。データ解析には、SD法による絶対評価法を用
いた。Test Example 1 (Experimental Material) As the experimental material, the liquid agent of Example 1 (Sample A) and the liquid agent of Example 1 from which Stevia was removed (Sample B) were used as experimental materials. (Test method) About questionnaire survey on flavor 1) Panelists: healthy adults in their 20s to 50s: 30
First name (male: 13 people, female: 17 people). 2) Content: Have sample A and sample B be drunk, and then
We used a method of answering a questionnaire. The evaluation method of the questionnaire is that each evaluation item (smell / fragrance, sweetness, sourness, spiciness, bitterness, astringency, afterglow,
Furthermore, (i) Deliciousness (ii) Medication-likeness (iii) Efficacy (iv) Repeated drinking (v) Purchase motive (vi) Overall evaluation)
Was evaluated in 7 stages (very good, relatively good, somewhat good, neither, slightly bad, relatively bad, very bad). In addition, the sample administration is performed by double blind, and the contents are not understood by the panelists. An absolute evaluation method based on the SD method was used for data analysis.
【0021】(試験結果)パネラーを用いて、検体A、
Bについて匂い/香り、甘味、酸味、辛味、
苦味、渋み、えぐみ、こく、後味について感じ方
と好みの評価を行った。その結果を図1、図2及び図3
に示す。感じ方、好みともステビアを用いた検体Aは、
検体Bに対して全ての評価群において改善効果の傾向が
示された。特に、感じ方では、甘味、苦味、及び後味の
改善効果について有意差を生じた(p<0.05)。ま
た、好みについても、苦味(p<0.01)、こく、甘
味、辛味及び後味(p<0.05)で改善効果を示し
た。(Test Results) Using a panel, the sample A,
About B Smell / aroma, sweetness, sourness, spiciness,
The feeling and taste of bitterness, astringency, acridness, body, and aftertaste were evaluated. The results are shown in FIG. 1, FIG. 2 and FIG.
Shown in Specimen A using Stevia for both feeling and preference
The tendency of the improving effect was shown in all the evaluation groups for the specimen B. In particular, regarding the feeling, there was a significant difference in the effect of improving sweetness, bitterness and aftertaste (p <0.05). Further, regarding the taste, the improvement effects were shown in the bitterness (p <0.01), body, sweetness, spiciness and aftertaste (p <0.05).
【0022】さらに、風味評価として(i)おいしさ、
(ii)薬らしさ、(iii)効き目感、(iv)繰り返しの
飲用、(v)購入動機、(vi)総合評価に関しても評価
を行った。Further, as a flavor evaluation, (i) deliciousness,
Evaluations were also made regarding (ii) drug-likeness, (iii) feeling of efficacy, (iv) repeated drinking, (v) purchase motive, and (vi) comprehensive evaluation.
【0023】その結果、検体Aは、検体Bに対して改善
効果が得られた。特に、おいしさと総合評価について
は、有意差を生じた(p<0.05)。As a result, the improvement effect of the sample A on the sample B was obtained. In particular, regarding the deliciousness and the overall evaluation, a significant difference was generated (p <0.05).
【0024】以上の結果から、甘味料としてステビアを
用いることは、有効成分由来の薬の苦味成分をマスキン
グすることが示唆された。The above results suggest that the use of stevia as a sweetener masks the bitterness component of the drug derived from the active ingredient.
【図1】検体A及びBを服用したときの風味評価(感じ
方)を表すグラフである。FIG. 1 is a graph showing flavor evaluation (how to feel) when samples A and B are taken.
【図2】検体A及びBを服用したときの風味評価(好
み)を表すグラフである。FIG. 2 is a graph showing flavor evaluation (preference) when the samples A and B are taken.
【図3】検体A及びBを服用したときの風味評価を表す
グラフである。FIG. 3 is a graph showing flavor evaluation when the samples A and B are taken.
Claims (1)
ール、塩酸ジフェンヒドラミンおよびマレイン酸クロル
フェニラミンからなる群より選ばれる一種または二種以
上の薬物および(b)ステビアを含有することを特徴と
する鎮暈剤。1. An anti-depressant agent containing (a) one or more drugs selected from the group consisting of meclizine hydrochloride, diphenidol hydrochloride, diphenhydramine hydrochloride and chlorpheniramine maleate, and (b) stevia. .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8094342A JPH0920653A (en) | 1995-05-02 | 1996-04-16 | Dizziness suppressing agent |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7-108502 | 1995-05-02 | ||
JP10850295 | 1995-05-02 | ||
JP8094342A JPH0920653A (en) | 1995-05-02 | 1996-04-16 | Dizziness suppressing agent |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH0920653A true JPH0920653A (en) | 1997-01-21 |
Family
ID=26435612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8094342A Pending JPH0920653A (en) | 1995-05-02 | 1996-04-16 | Dizziness suppressing agent |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0920653A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013216632A (en) * | 2012-04-11 | 2013-10-24 | Rohto Pharmaceutical Co Ltd | Pharmaceutical composition |
CN103543231A (en) * | 2012-07-11 | 2014-01-29 | 北大方正集团有限公司 | Separation analysis method of residual amount of chloroform in meclizine dihydrochloride |
JP2017014292A (en) * | 2016-10-24 | 2017-01-19 | ロート製薬株式会社 | Pharmaceutical composition |
-
1996
- 1996-04-16 JP JP8094342A patent/JPH0920653A/en active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013216632A (en) * | 2012-04-11 | 2013-10-24 | Rohto Pharmaceutical Co Ltd | Pharmaceutical composition |
CN103543231A (en) * | 2012-07-11 | 2014-01-29 | 北大方正集团有限公司 | Separation analysis method of residual amount of chloroform in meclizine dihydrochloride |
CN103543231B (en) * | 2012-07-11 | 2015-09-16 | 北大方正集团有限公司 | The method for separating and analyzing of chloroform residual quantity in a kind of meclozine hydrochloride |
JP2017014292A (en) * | 2016-10-24 | 2017-01-19 | ロート製薬株式会社 | Pharmaceutical composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW546143B (en) | Comprising vitamin p and a processed product of Pfaffia extract | |
JPH09110708A (en) | Pharmaceutical preparation comprising crude drug for nourishment and robust | |
JP4051717B2 (en) | Biotin-containing oral solution | |
JP2013177418A (en) | Pharmaceutical composition including rebamipide | |
KR20100135316A (en) | Liquid formulation for deferiprone with palatable taste | |
JP2002363105A (en) | Method for masking unpleasant taste and solution for oral administration | |
JPH0952825A (en) | Antipyretic and analgesic agent | |
JP2002348236A (en) | Liquid drug | |
JP4403590B2 (en) | Vitamin B1 combination liquid | |
CN112912070A (en) | Therapeutic or prophylactic agent for nocturnal polyuria | |
JPH0920653A (en) | Dizziness suppressing agent | |
JP2004161679A (en) | Liquid preparation for internal use | |
JPH10245343A (en) | Oral composition for improving body small | |
JP3479986B2 (en) | Composition for preventing alcoholic liver injury | |
JP3228534B2 (en) | Composition for lowering blood alcohol concentration | |
JPH0952838A (en) | Composition for oral use | |
JPH0952829A (en) | Muscle relaxant | |
JPH0920670A (en) | Anti-choline agent | |
JPH0930969A (en) | Oral composition | |
KR102310813B1 (en) | Composition for relieving hangover comprising matured silkworm and yeast extract as an active ingredient | |
JP2000273051A (en) | Liquid preparation whose bitter taste is masked | |
JP2006022056A (en) | Agent for preventing getting drunk | |
JP2005023008A (en) | Internal liquid medicine composition containing vitamin b group | |
JPH0952827A (en) | Composition for oral administration | |
JPH0920654A (en) | Bronchodilator |